• Amit Sood, Jon O Ebbert, Kirk D Wyatt, Ivana T Croghan, Darrell R Schroeder, Richa Sood, and J Taylor Hays.
• Mayo Clinic College of Medicine, 200 1st Street Southwest, Rochester, MN 55905, USA.
• Nicotine Tob. Res. 2010 Mar 1; 12 (3): 300-4.

IntroductionWe conducted a preliminary proof-of-concept study evaluating gabapentin for the treatment of tobacco dependence.MethodsSubjects (N = 80) were randomized to gabapentin (600 mg three times per day or 900 mg three times per day) or placebo. After a 2-week dose titration, the target dose was maintained for 9 weeks and then tapered over 1 week. Follow-up was for 12 weeks after the medication phase.ResultsThe study had high dropout rates with more than one half of participants in each arm discontinuing study. Gabapentin-treated participants exhibited lower abstinence rates than placebo-treated participants; however, this difference was not significant. Smoking reduction was observed across all treatment arms compared with baseline (p < .01) but did not differ across treatment groups.DiscussionAlthough not definitive, our findings suggest that gabapentin administered at these doses with this dosing regimen holds little promise for the treatment of tobacco dependence in a population of smokers seeking treatment.

18 keywords...

hide…